Imbruvica Combo Improves Long-term Survival in CLL/SLL Patients, Updated Phase 3 Results Show
News
Combining AbbVie’s Imbruvica (ibrutinib) with Treanda (bendamustine) and Rituxan (rituximab) improves long-term survival outcomes in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer reappeared or ... Read more